Global ingredient manufacturer Kemin Industries received a U.S. patent for the use of a proprietary strain of algae in treating human immune function and intestinal inflammation, the company announced this week. This is Kemin’s second patent featuring the beta-glucan in Kemin’s BetaVia Complete and BetaVia Pure ingredients. In the functional ingredient market, algae surpassed $800 million in 2018 and is forecast to grow faster than 7% compound annual growth rate through 2027, the company said in a statement.
